Gattex

NPS Buys Back Rights to Gattex From Takeda to Spur Sales

NPS Buys Back Rights to Gattex From Takeda to Spur Sales

Bloomberg

NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It

NPS Pharmaceuticals Chief: Why 250k-a-Year Orphan Drug is Worth It

Y Charts

3 Drug Launches You Need to Know in 2013

3 Drug Launches You Need to Know in 2013

Motley Fool

4 FDA Approvals in 1 Day

4 FDA Approvals in 1 Day

Motley Fool

NPS Gattex Wins Approval for Short-Bowel Syndrome

NPS Gattex Wins Approval for Short-Bowel Syndrome

Bloomberg

3 Things to Watch at NPS Pharmaceuticals

3 Things to Watch at NPS Pharmaceuticals

Motley Fool

NPS Pharma Drifts Higher On Potential Orphan Drug Approval

NPS Pharma Drifts Higher On Potential Orphan Drug Approval

Seeking Alpha

FDA panel votes to support NPS Pharma bowel drug

FDA panel votes to support NPS Pharma bowel drug

Yahoo/AP

NPS shares halted as FDA panel reviews bowel drug

NPS shares halted as FDA panel reviews bowel drug

Yahoo/AP

NPS Pharmaceuticals: Buy If There Is A Dip

NPS Pharmaceuticals: Buy If There Is A Dip

Seeking Alpha